查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球風疹診斷測試市場 - 2023-2030
市場調查報告書
商品編碼
1347975

全球風疹診斷測試市場 - 2023-2030

Global Rubella Diagnostic Testing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

麻疹具有高度傳染性。大約十分之九未受到保護的人會在接觸麻疹病毒後被感染。懷孕早期感染風疹的孕婦生出患有先天性風疹症候群（CRS）的嬰兒的可能性高達 90%。一名麻疹患者可感染 12 至 18 人，使其成為傳染性最強但可通過疫苗預防的疾病。

接觸麻疹的易感人群（未接種疫苗/從未患過麻疹）中約有十分之九會患病。 33% 患有先天性風疹症候群的嬰兒在一歲之前死亡。風疹 IgG 血清學檢測應用於評估風疹免疫力，包括懷疑先天性風疹症候群的懷孕前、懷孕期間和懷孕後。懷孕期間感染風疹可導致流產（受孕 20 週內胎兒流產）和死產（20 週後死亡）。

市場動態

世界某些地區麻疹疫情增加

世界某些地區再次爆發麻疹疫情增加了診斷檢測。美國疾病控制與預防中心的數據顯示，儘管美國在2000年就宣布麻疹被消滅，但2019年美國31個州報告了近1300例麻疹病例，是1992年以來的最高數位。世界衛生組織於2023 年8 月上旬表示，與世界其他國家相比，印度的麻疹病例數最多，截至2023 年有57,550 例。也門有24,596 例，巴基斯坦有10,549 例。

2000 年至 2021 年間，麻疹疫苗在全球挽救了超過 5600 萬人的生命。然而，由於其再次發生，這一數位正在下降。診斷測試可用於治療生活在觀察到麻疹疫情的特定地區的個人的疾病。據聯合國國際兒童緊急基金會（UNICEF）稱，全球疫苗接種覆蓋率已於2022年恢復。然而，全球仍有2050萬兒童錯過了救生疫苗，比2019年增加了210萬。

2022 年，儘管印度的覆蓋率達到 93%，但仍有 160 萬兒童未接種疫苗和疫苗接種不足。數量的減少使得該疾病在少數地區再次出現，並立即傳播到其他地區，因為該疾病具有高度傳染性。疫情發生在疫苗接種率最低的地區。因此，預計上述因素將在預測期內推動市場。

推動市場的其他一些因素包括測試程序的進步、風疹疫情的再次爆發以及疫苗接種數量的減少，這些因素預計將在未來一段時間內推動市場。

孕婦檢測結果呈假陽性

風疹 IgM 檢測應僅限於疑似風疹病例。不建議用於篩查無症狀人群。類風濕因子的存在也可能導致 IgM 假陽性。由於存在假陽性結果的可能性，IgM 不應包含在常規檢測中以確定先前風疹免疫的證據。對無症狀、未暴露的孕婦進行風疹 IgM 檢測是不合適的，因為可能會出現假陽性結果，從而產生誤導。

目錄

第 1 章：方法和範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義和概述

第 3 章：執行摘要

  • 診斷測試片段
  • 按年齡層分類
  • 最終用戶的片段
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 動力
      • 世界某些地區麻疹疫情不斷增加
    • 限制
      • 孕婦的假陽性檢測結果
    • 機會
    • 影響分析

第 5 章：行業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情后的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商戰略舉措
  • 結論

第 7 章：通過診斷測試

  • 乳膠凝集
  • 肝功能檢查
  • 酶免疫分析 (EIA)
  • 放射免疫分析（RIA）
  • 螢光免疫分析 (FIA)
  • 其他

第 8 章：按年齡層

  • 新生兒
  • 青少年
  • 成年人

第 9 章：最終用戶

  • 醫院和診所
  • 診斷實驗室
  • 門診手術中心
  • 其他

第 10 章：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Siemens Healthineers AG
    • 公司簡介
    • 診斷技術組合和描述
    • 財務概覽
    • 主要進展
  • Bio Rad Laboratories Inc.
  • Abbott Laboratories
  • BioMerieux SA
  • Thermo Fisher Scientific Inc.
  • ZEUS Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics
  • InDevR, Inc.
  • Beckman Coulter Inc.

第 13 章：附錄

簡介目錄
Product Code: CD2133

Overview

Measles is highly contagious. Around 9 out of 10 people who are not protected will become infected following exposure to the measles virus. A pregnant woman infected with rubella in early pregnancy has up to a 90% chance of giving birth to a baby with congenital rubella syndrome (CRS). One person with measles can infect 12-18 people, making it the most infectious yet vaccine-preventable disease.

Around 9 out of 10 susceptible people (unvaccinated/have never had measles) who are exposed to measles will get sick. 33% of infants with congenital rubella syndrome die before one year. Rubella IgG serology testing should be used for assessing rubella immunity, including before, during, and after pregnancy suspecting congenital rubella syndrome. Rubella infection during pregnancy can lead to miscarriage (loss of the fetus within 20 weeks of conception) and stillbirth (death after 20 weeks).

Market Dynamics

Increasing measles outbreaks in certain parts of the world

The Reoccurrence of measles outbreaks in some parts of the world increases diagnostic testing. According to the Centers for Disease Control and Prevention, although measles was declared eliminated in the United States in 2000, almost 1,300 cases of measles were reported in 31 states in the U.S. in 2019, the most significant number since 1992. According to data, the World Health Organization said in early August 2023, India had the highest number of measles cases compared to the rest of the world, with 57,550 cases as of 2023. Yemen with 24,596 and Pakistan with 10,549 patients.

Measles vaccines saved more than 56 million lives worldwide between 2000-2021. However, the numbers are declining due to its reoccurrence. Diagnostic testing comes into play to treat the disease in individuals living in specific regions where measles outbreaks are observed. According to the United Nations International Children's Emergency Fund (UNICEF), global vaccination coverage has recovered in 2022. However, there are still 20.5 million children missing out on lifesaving vaccines globally, 2.1 million more than in 2019.

In 2022, India accounted for 1.6 million unvaccinated and under-vaccinated children despite achieving 93 percent coverage. These reducing numbers make the reoccurrence of the disease in a few regions and immediately spread to other regions as well because the disease is highly contagious. The outbreaks happen in those areas where the vaccination is at its lowest. Hence, the above factor is expected to drive the market in the forecast period.

Some of the other factors that drive the market are advancements in testing procedures, reoccurrence of rubella outbreaks, and decreased number of vaccinations are a few factors that are expected to drive the market in the forthcoming period.

False positive test results in pregnant women

Rubella IgM testing should be limited to suspected rubella cases. It is not recommended for screening asymptomatic people. The presence of rheumatoid factor can also result in a false positive IgM. Due to the possibility of false positive results, IgM should not be included in routine testing to determine evidence of prior rubella immunity. Rubella IgM testing in asymptomatic, unexposed pregnant people is inappropriate because false positive results can occur, which can be misleading.

Segment Analysis

The global rubella diagnostic testing is segmented based on diagnostic test, age group, end user, and region.

The enzyme immunoassay (EIA) is expected to hold the largest market share during the forecast period, owing to the rising incidences of rubella and the advantages of the enzyme immunoassay (EIA) method. For instance, the enzyme immunoassay is the most used as it is relatively inexpensive, technically easy to perform, rapid, and susceptible.

EIA is used to detect rubella-specific immunoglobulin G (IgG) antibodies. IgM testing is the most commonly performed technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies the immune system makes to kill the rubella virus, which remains in the bloodstream for years. The EIA is also suitable for diagnosing acute infections, as a significant increase in antibody levels was detected in all paired specimens tested from patients with acute rubella infection.

In July 2021, it reported that measles and rubella are two of the most globally critical vaccine-preventable diseases (VPD), and measuring antibodies to measles and rubella viruses in samples collected from serosurveys can play an important role in estimating population immunity and guiding immunization activities and enzyme immunoassay is the most convenient method and accessible approach for detecting the rubella virus. Hence, the efficacy is elevated if ELISA kits are used. This factor is expected to drive the market in the forecast period.

Geographical Analysis

Asia Pacific is expected to hold the largest segment in the market. According to information from the Centers for Disease Control and Prevention, India has the highest number of cases between April and September 2022. Pakistan stayed in 7th position with 3635 cases, while the US had 33 cases by the end of 2022.

Due to the increased number of cases in 2022, the Indian government has launched a scheme to improve the diagnostic services related to measles disease. For instance, in July 2022, the Pradhan Mantri Surakshit Matritva Abhiyan by the Ministry of Health & Family Welfare (MoHFW), Government of India, to improve the quality and coverage of antenatal care (ANC), including diagnostics and counseling services, as part of the Reproductive Maternal Neonatal Child and Adolescent Health (RMNCH + A) strategy.

COVID-19 Impact Analysis on Rubella Diagnostic Testing Market

COVID-19 negatively impacted the global market during the outburst because to prevent further COVID-19 infection, restrictions and regulations were imposed, making it difficult for people to perform rubella diagnoses affecting the sales of the rubella diagnostic kits. Furthermore, during the pandemic, regular vaccination programs were on hold, which according to NIH estimation, put 80 million infants at risk of infection by measles, polio, and diphtheria, negatively impacting the global market.

Market Segmentation

By Diagnostic Technique

  • Latex Agglutination
  • Liver Function Tests
  • Enzyme Immunoassay (EIA)
  • Radioimmunoassay (RIA)
  • Fluorescent Immunoassay (FIA)
  • Others

By Age Group

  • Neonates
  • Teenagers
  • Adults

By End User

  • Hospitals and Clinics
  • Cancer Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the rubella diagnostic testing market include: Siemens Healthineers AG, Bio Rad Laboratories Inc., Abbott Laboratories, BioMerieux SA, Thermo Fisher Scientific Inc., ZEUS, Scientific Inc., F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, InDevR, Inc., and Beckman Coulter Inc. among others.

Key Developments

  • In 2023, The Immunization Agenda 2030 Measles & Rubella Partnership (M&RP), a partnership led by the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccines Alliance, the Bill and Melinda French Gates Foundation, UNICEF and WHO, to achieve the IA2030 measles and rubella specific targets.
  • In August 2022, Roche reported that the United States Food and Drug Administration (USFDA) has approved a label expansion for its Ventana MMR RxDx Panel that provides clinicians with access to a fully automated panel of mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).
  • In 2021, The United Kingdom Health Security Agency's Immunization and Vaccine-Preventable Diseases Division launched a new rash-fever surveillance scheme. The aim is to increase the number of samples tested for measles and rubella diagnostic testing. The program was initiated by the United Kingdom government, which distributed rubella diagnostic kits for rapid rubella testing.

Why Purchase the Report?

  • To visualize the global rubella diagnostic testing segmentation based on diagnostic test, age group, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of rubella diagnostic testing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global rubella diagnostic testing market report would provide approximately 61 tables, 61 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Diagnostic test
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Measles Outbreaks in Certain Parts of the World
    • 4.1.2. Restraints
      • 4.1.2.1. False Positive Test Results in Pregnant Women
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnostic test

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test
    • 7.1.2. Market Attractiveness Index, By Diagnostic Test
  • 7.2. Latex Agglutination*
    • 7.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test
    • 7.2.2. Market Attractiveness Index, By Diagnostic Test
  • 7.3. Liver Function Tests
  • 7.4. Enzyme Immunoassay (EIA)
  • 7.5. Radioimmunoassay (RIA)
  • 7.6. Fluorescent Immunoassay (FIA)
  • 7.7. Others

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Neonates*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Teenagers
  • 8.4. Adults

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic laboratories
  • 9.4. Ambulatory surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Siemens Healthineers AG
    • 12.1.1. Company Overview
    • 12.1.2. Diagnostic technique Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bio Rad Laboratories Inc.
  • 12.3. Abbott Laboratories
  • 12.4. BioMerieux SA
  • 12.5. Thermo Fisher Scientific Inc.
  • 12.6. ZEUS Scientific Inc.
  • 12.7. F. Hoffmann-La Roche Ltd
  • 12.8. Ortho Clinical Diagnostics
  • 12.9. InDevR, Inc.
  • 12.10. Beckman Coulter Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us